University of Ioannina
Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: the role of diabetes duration and overt cardiovascular disease
Abstract
dc:descriptionThe purpose of this study was to assess vascular function in patients with Type 2 Diabetes mellitus (DM2) with and without established cardiovascular disease (CVD) by using non invasive markers of subclinical atherosclerosis, as well as to examine the association of endothelial dysfunction with diabetes duration and glycemic control. The prevalence of diabetes mellitus has been increased significantly and has been considered as a growing epidemic. The need for effective intervention is therefore urgent. Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death in persons with type 2 diabetes mellitus (T2DM), resulting in significant morbidity and increasing health care costs. Even in the pre-diabetic range, individuals suffering from T2DM are predisposed to significant cardiovascular risk. Moreover, they often remain asymptomatic and when they develop clinically evident CVD, their prognosis and outcomes are worse compared to individuals with CVD but without DM2. Large epidemiological studies have established the role of hyperglycemia as a risk factor for the development of both microvascular and macrovascular complications. Hyperglycemia alters the protective mechanisms of the endothelium and leads to inflammatory damage of the endothelial wall, increased permeability, as well as reduction of antiatherogenic vasodilators, such as nitric oxide. Endothelial dysfunction has been previously reported in persons with T2DM as well as prediabetes compared to healthy subjects, while comorbidities such as hypertension and dyslipidemia seem to have a synergistic effect leading to accelerated atherogenesis. Despite the evidence linking hyperglycemia (even in the pre-diabetic range) with CVD, several large randomized controlled trials have failed to show a cardiovascular benefit from strict glycemic control in patients with long-standing T2DM at high CVD risk (DECODE 1999, UKPS 1998, Skyler 2009). Although DM2 was initially characterized as CVD risk equivalent, through the years it has become more evident that not all diabetics are at the same risk. Therefore, a proper risk stratification might help to identify those who are more likely to benefit from risk factor modifications. So, the aim of the initial baseline study was to assess vascular dysfunction by using brachial artery flow-mediated dilation (FMD), carotid-femoral pulse wave velocity (cfPWV), central augmentation index(AIx), large (C1) and small (C2) artery compliance, carotid intima-media thickness (cIMT), and ankle-brachial index (ABI) in poorly controlled DM2 persons with and without overt CVD as well as to examine the role of DM2 duration.Patients who participated in our study with T2DM were prospectively recruited from the Department of Endocrinology, Ioannina University Hospital and the Diabetes Outpatient Clinic, Chatzikosta General Hospital of Ioannina. A careful evaluation was made regarding diabetes duration and macrovascular complications. The following indices of vascular function were measured in all patients: common carotid intima-media thickness, (cIMT), brachial artery flow-mediated dilation (FMD), carotid-femoral pulse wave velocity (cfPWV), central augmentation index (AIx@75), large (C1) and small artery elasticity indices (C2) and ankle-brachial index (ABI). The baseline study included 95 persons with T2DM and poor glycemic control were included and divided into two groups, with and without known CVD. The latter were further subdivided into two subgroups according to diabetes duration (longer duration > 5 years after T2DM diagnosis). The results showed that the presence of macrovascular disease was associated with more pronounced vascular dysfunction, as assessed with those non-invasive markers of subclinical atherosclerosis. Furthermore, patients with relatively short duration of diabetes (<5 years since diagnosis) had a significantly better vascular profile.The follow -up study aimed to investigate the effect of intensive antidiabetic treatment on vascular indices in patients with DM2. The same markers of subclinical atherosclerosis were assessed before and after improvement of glycemic control. Patients who did not achieve an absolute HbA1c reduction of at least 0.5% were excluded from the final analysis. They were regularly seen as required, provided with all necessary prescriptions regarding lipid-lowering treatment etc, and were encouraged to follow lifestyle modification as well. The study showed that in patients with long-standing T2DM, short-term aggressive glycemic control at a median follow up of 9 months was associated with an improvement of microvascular function (C2) and deterioration of carotid atherosclerosis (IMT) without any effect on the elastic properties of large arteries. Moreover, the duration of established diabetes or the presence of CVD did not seem to alter the effects of glycaemic control on these markers in this cohort. To our knowledge, this was also the first study to report on the effects of intensive glycemic control on several markers of subclinical atherosclerosis in T2DM patients of variable disease duration, including patients with established macrovascular disease.A multifactorial approach including improvement of lipid profile, arterial blood pressure and lifestyle interventions may be more appropriate in order to achieve a delay in atherosclerosis progression and induce further improvements in other vascular indices. The duration of diabetes, the history of established cardiovascular atherosclerotic disease as well insulin treatment did not significantly affect the changes produced by our intervention. Further studies are needed to investigate whether multifactorial interventions, improvement of glycemic control with newer antidiabetic agents (i.e. GLP-1 agonists and SGLT2 inhibitors) and a longer duration of intervention may be more effective in improving vascular indices in patients with T2DM.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Antoniou, Sofia
- Αντωνίου, Σοφία
Subjects
dc:subject × 12- Διαβήτης (σακχαρώδης)
- Καρδιαγγειακές δοκιμασίες
- Καρδιαγγειακός κίνδυνος
- Diabetes control
- Atherosclerosis, Subclinical
- Chronic complications of diabetes mellitus
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53977